Business context and reporting period
Repligen Corporation reported on October 6, 2026 that it completed its previously announced acquisition of BioLife Solutions, Inc. The filing reports the transaction closing, not results for a financial reporting period.
Transaction terms and key financial information
- Each eligible BioLife common share converted into $11.25 in cash plus 0.1442 Repligen common shares. Fractional shares were paid in cash.
- BioLife options, restricted stock units, performance-based units, and restricted stock awards were accelerated or settled before closing; the resulting shares received the merger consideration.
- The filing does not provide a clear value for total consideration, acquired revenue or profit, transaction financing, debt, liquidity, cash flow, or expected costs and synergies. It contains no standalone financial results or margin data.
Material changes versus the prior comparable period
This is a transaction-completion report and does not provide comparable-period financial results. BioLife became a wholly owned subsidiary of Repligen through a two-step merger. BioLife ceased to exist as a separate legal entity, and its common stock is to be delisted from Nasdaq and deregistered.
Outlook, contingencies, and unusual items
- The filing provides no financial guidance, forecast, or management commentary on expected operating performance.
- BioLife equity awards accelerated or vested in connection with closing, including performance-based awards measured using the greater of target or actual achievement as of the latest practicable date before closing.
- Repligen stated it intends to file acquired-business financial statements and pro forma information by amendment within 71 calendar days after the filing was required, if required.
- The filing notes that merger-agreement representations and warranties are subject to qualifications and should not be relied on as establishing factual matters.
Investor facts to verify
- Review the forthcoming acquired-business and pro forma financial information, if filed, for the acquisition’s financial impact.
- Confirm the final transaction value, including shares issued, cash paid, and any treatment of appraisal claims or fractional shares.
- Assess how the acquisition affects Repligen’s financing, debt, liquidity, integration costs, and future guidance; these details are not provided in this filing.